Navigation Links
Par Pharmaceutical Files Form 10-Qs for First and Second Quarters of 2007
Date:11/21/2007

Revises 2007 Full-Year Financial Outlook

WOODCLIFF LAKE, N.J., Nov. 21 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today filed with the U.S. Securities and Exchange Commission (SEC) its Form 10-Q for the first and second quarters of 2007. The filing of Par's Form 10-Qs for these periods had been delayed due to the work involved in restating its consolidated financial statements for certain prior periods, which were filed earlier this year.

First-Quarter Results

For the first quarter ended March 31, 2007, Par reported total revenues of $234.2 million and net income of $41.5 million, or $1.19 per diluted share. This is compared with reported revenues of $172.3 million and net income of $4.5 million, or $0.13 per diluted share, for the same period in 2006.

First quarter 2007 reported, or GAAP, results included a $20.0 million gain on the sale to Optimer Pharmaceutical, Inc. of marketing rights to the investigational drug Difimicin (Par 101), a $1.4 million investment gain on the sale of shares of Optimer common stock, and net settlement gains of $0.6 million related to the discontinuation of certain product-development agreements. Adjusting for these items, net income for the first quarter of 2007 was $28.1 million, or $0.80 per diluted share.

First-Quarter Review

For the first quarter ended March 31, 2007, total revenues increased 35.9 percent compared with the same period in 2006 due primarily to new product introductions. These products include propranolol HCl extended release (ER) capsules, metoprolol succinate, polyethylene glycol, and ranitidine HCl syrup achieving sales of $31.3 million, $12.3 million, $4.3 million and $4.2 millionreasury stock, at cost 941,035 and

920,558 and 889,245 shares (34,521) (33,933) (33,188)

Total stockholders' equity 476,383 468,800 421,009

Total liabilities and stockholders'

equity $838,237 $863,416 $814,677

PAR PHARMACEUTICAL COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data)

(Unaudited)

Three months ended

March 31, April 1,

2007 2006

Revenues:

Net product sales $222,589 $169,037

Other product related revenues 11,621 3,281

Total revenues 234,210 172,318

Cost of goods sold 146,521 123,150

Gross margin 87,689 49,168

Operating expenses:

Research and development 14,039 13,852

Selling, general and administrative 32,557 28,342

Settlements, net (578) -

Total operating expenses 46,018 42,194

Gain on sale of product rights (20,000) -

Operating income 61,671 6,974

Other expense, net (19) (39)

Equity in loss of joint venture (148) (253)

Realized gain on sale of marketable securities 1,397 -

Interest income 2,684 1,983

Interest expense (1,718) (1,694)

Income before provision for income taxes 63,867 6,971

Provision for income taxes 22,353 2,457

Net income $41,514 $4,514

Earnings per share of common stock:

Basic $1.20 $0.13

Diluted $1.19 $0.13

Weighted average number of

common shares outstanding:

Basic 34,618 34,259

Diluted 34,997 34,766

PAR PHARMACEUTICAL COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data)

(Unaudited)

Three months ended Six months ended

June 30, July 1, June 30, July 1,

2007 2006 2007 2006

Revenues:

Net product sales $160,014 $190,583 $382,603 $359,620

Other product related

revenues 7,626 4,655 19,247 7,937

Total revenues 167,640 195,238 401,850 367,557

Cost of goods sold 111,085 140,471 257,606 263,621

Gross margin 56,555 54,767 144,244 103,936

Operating expenses:

Research and development 14,277 17,557 28,316 31,409

Selling, general and

administrative 33,999 42,941 66,556 71,283

Settlements, net - 1,250 (578) 1,250

Total operating expenses 48,276 61,748 94,294 103,942

Gain on sale of product

rights - - (20,000) -

Operating income (loss) 8,279 (6,981) 69,950 (6)

Other expense, net (30) 142 (49) 104

Equity in loss of joint venture (80) (225) (228) (479)

Loss on marketable securities,

net (6,040) (3,773) (4,643) (3,773)

Interest income 3,901 1,973 6,585 3,956

Interest expense (1,727) (1,693) (3,445) (3,388)

Income (loss) before provision

(benefit) for income taxes 4,303 (10,557) 68,170 (3,586)

Provision (benefit) for income

taxes 1,505 (3,352) 23,858 (896)

Net income (loss) $2,798 $(7,205) $44,312 $(2,690)

Earnings (loss) per share of

common stock:

Basic $0.08 $(0.21) $1.28 $(0.08)

Diluted $0.08 $(0.21) $1.27 $(0.08)

Weighted average number of

common shares outstanding:

Basic 34,676 34,454 34,647 34,368

Diluted 34,943 34,454 34,970 34,368

Reconciliation Between Reported (GAAP) and Adjusted Net Income (Loss)

(In thousands, except per share data)

(Unaudited)

Three Months Ended

March 31, April 1,

2007 2006

Reported Net Income $41,514 $4,514

Gain on Sale of Product Rights (20,000) -

Investment Gain (1,397) -

Net Settlements Gain (578) -

Estimated Tax on Adjustments 8,570 -

Adjusted Net Income (non-GAAP measure) $28,109 $4,514

Diluted Earnings Per Share:

Reported $1.19 $0.13

Adjusted (non-GAAP measure) $0.80 $0.13

Three Months Ended

June 30, July 1,

2007 2006

Reported Net Income (Loss) $2,798 $(7,205)

Net Investment Loss 6,040 3,773

License Fee 3,000 -

Severance Costs 1,643 -

Write-off of Accounts Receivable Relating to

Invalid Customer Deductions - 9,965

Arbitration Settlement - 1,502

Estimated Tax on Adjustments (4,166) (5,944)

Adjusted Net Income (non-GAAP measure) $9,315 $2,091

Diluted Earnings (Loss) Per Share:

Reported $0.08 $(0.21)

Adjusted (non-GAAP measure) $0.27 $0.06

Reconciliation Between Reported (GAAP) and Adjusted Net Income (Loss)

(In thousands, except per share data)

(Unaudited)

Six Months Ended

June 30, July 1,

2007 2006

Reported Net Income (Loss) $44,312 $(2,690)

Gain on Sales of Product Rights (20,000) -

Net Investment Loss 4,643 3,773

License Fee 3,000 -

Severance Costs 1,643 -

Net Settlements Gain (578) -

Write-off of Accounts Receivable Relating to

Invalid Customer Deductions - 9,965

Arbitration Settlement - 1,502

Estimated Tax on Adjustments 4,404 (5,944)

Adjusted Net Income (non-GAAP measure) $37,424 $6,606

Diluted Earnings (Loss) Per Share:

Reported $1.27 $(0.08)

Adjusted (non-GAAP measure) $1.07 $0.19

Estimated Operating Results for Full Year 2007

Total Revenue $760 - $780 million

SG&A $130 - $133 million

R&D $75 - $80 million

EPS (fully diluted) $1.35 - $1.50

Other supplemental information

Depreciation & amortization $24 - $26 million

Share-based compensation $18 - $20 million

IMPACT OF ONE-TIME ITEMS FY 2007

(in millions, except per share amounts)

Severance $2

Branded Milestone Payments 19

High Yield Investment Loss 6

PAR 101 (24)

Total One-Time Items $3

EPS Impact (fully diluted) $0.05

EPS (fully diluted)

adjusted for one-time items $1.40 - $1.55

, respectively. Partially offsetting the increases were lower sales of certain existing products due to competitive pressures, including fluticasone, paroxetine, tramadol HCl and cefprozil. Revenues of branded products for the first quarter of 2007 of $19.5 million, an increase of 137 percent over the prior year period, were driven by increased sales of Megace(R) ES (megestrol acetate) oral suspension, and fees related to the co-promotion of AndroGel(R).

Par's first-quarter gross margin was 37.4 percent of sales, compared to 28.5 percent in 2006. The increase in the Company's gross margin resulted primarily from increased sales of higher-margin products, including Megace(R) ES and propranolol ER, royalties related to the sale of ondansetron orally disintegrating tablets and the co-promotion fee for AndroGel(R).

Research and development (R&D) expenses increased 1.3 percent for the first quarter 2007 compared with the first quarter 2006. The results reflect increased development costs in support of Par's generic product portfolio tempered by reduced clinical development costs following the termination of the megestrol acetate concentrated suspension oncology study in 2006 and the termination of Par's participation in the development of Par 101, as well as lower personnel costs following the restructuring of the R&D organization.

Selling, general and administrative (SG&A) expenses for the first quarter 2007 increased 14.9 percent from first quarter 2006. The increase is primarily due to an increase of the field sales force for Strativa, the Company's branded division, as well as the expansion of the finance and accounting functions and increased professional costs associated with the Company's restatement.

Second-Quarter and Six-Month Results

For the second quarter ended June 30, 2007, Par reported total revenues of $167.6 million and net income of $2.8 million, or $0.08 per diluted share. This is compared with reported revenues of $195.2 million and a net loss of $7.2 million, or $0.21 per diluted share, for the same period in 2006. For the six months ended June 30, 2007, Par reported total revenues of $401.9 million and net income of $44.3 million, or $1.27 per diluted share. This is compared with reported revenues of $367.6 million and a net loss of $2.7 million, or $0.08 per diluted share, for 2006.

Second-quarter 2007 reported, or GAAP, results included a $6.0 million investment loss and a $3.0 million license fee paid to Immtech Pharmaceuticals for commercialization rights to the developmental drug pafuramidine maleate, both of which are discussed in more detail below, in addition to $1.6 million of severance costs. Adjusting for these items, net income for the second quarter of 2007 was $9.3 million, or $0.27 per diluted share. By comparison, second-quarter 2006 reported results included a write-off of approximately $10.0 million of accounts receivable relating to invalid customer deductions and $5.2 million of expense relating to the write-down of an equity investment and an arbitration settlement. Adjusting for these items, net income for the second quarter 2006 was $2.1 million, or $0.06 per diluted share.

Net income for the first six months of 2007 was $37.4 million, or $1.07 per diluted share, after adjusting for the aforementioned items. By comparison, reported results for the first six months of 2006 included the 2006 second-quarter items discussed above. Adjusting for these items, net income for the first six months of 2006 was $6.6 million, or $0.19 per diluted share. [See reconciliation between reported (GAAP) and adjusted net income (loss) at the end of this press release.]

Second-Quarter Review

For the second quarter ended June 30, 2007, total revenues decreased 14.1 percent compared with the same period a year earlier as increased competition resulted in lower sales of generic products. Among these products, sales of fluticasone nasal spray declined by $26.9 million from the second quarter of 2006. Partially offsetting these decreases were sales of recently introduced products. Among the products introduced since the end of the second quarter of 2006, metoprolol extended release (ER) 25 mg tablets achieved sales of $17.3 million and propranolol ER capsules contributed sales of $10.4 million. Par markets fluticasone in the U.S. through a supply and distribution agreement with GlaxoSmithKline. Par markets metoprolol ER in the U.S. through a supply and distribution agreement with AstraZeneca. Sales of Megace(R) ES (megestrol acetate) oral suspension increased 124 percent to $19.1 million in the second quarter.

Par's second-quarter gross margin was 33.7 percent of sales, compared to 28.1 percent in 2006. The increase in the Company's gross margin resulted primarily from increased sales of higher-margin products, including Megace(R) ES and propranolol ER, royalties related to the sale of ondansetron orally disintegrating tablets and the co-promotion fee for AndroGel(R).

Research and development (R&D) expense decreased 18.7 percent to $14.3 million in the second quarter of 2007, driven by reduced clinical development costs related to Megace(R) ES, the termination of Par's participation in the development of Par 101, as well as lower personnel costs. These reductions were partially offset by a $3.0 million license fee paid to Immtech Pharmaceuticals for commercialization rights to their lead oral drug candidate, pafuramidine maleate, which is being developed for the treatment of pneumocystis pneumonia in AIDS patients. In June 2007, Par entered into an exclusive licensing agreement with Immtech for U.S. commercialization rights.

Second-quarter selling, general and administrative (SG&A) expense decreased 20.8 percent to $34.0 million. The decrease in 2007 SG&A expense was primarily due to the second-quarter 2006 write-off of approximately $10.0 million of accounts receivable relating to invalid customer deductions.

In the second quarter of 2007, Par recorded a $6.0 million loss relating to an investment in a fund comprised of various floating-rate structured finance securities that experienced a severe reduction in value.

2007 Financial Outlook

Par has revised its previously announced guidance for full-year 2007 earnings per diluted share to $1.35-$1.50 from $0.95-$1.10. This increase is driven by a delay in the anticipated impact of competition on the pricing and volume environment of certain generic products, specifically, propanolol, fluticisone, metroprolol, and cabergoline. However, the Company is experiencing significant competition on price and volume of propranolol, fluticasone, and metroprolol in the fourth quarter.

The Company's projections are based on its results for the first six months of 2007 and management's assumption of the impact of product competition on some of Par's key products and include the impact of certain one-time items and lower SG&A costs.

Total net revenue is expected to be between $760-$780 million. SG&A is expected to be $130-$133 million, including approximately $2 million in severance costs. Research and development cost is projected to be in the range of $75-$80 million, including approximately $19 million in branded milestone payments. Total projected expenses for the full-year include approximately $18-$20 million of share-based compensation and $24-$26 million of depreciation and amortization expenses. Adjusting for one-time items, full year earnings per diluted share is projected to be $1.40-$1.55. [See summary of estimated operating results for full year 2007 at the end of this press release.]

Stock Repurchase Program

Since October 1, 2007, Par has repurchased 1,643,094 shares of its common stock at a total cost of $31.5 million. On September 28, 2007, Par announced that its Board of Directors had authorized the repurchase of up to $75 million of the company's common stock.

Conference Call

Par has scheduled a conference call for Wednesday, November 21 at 9:00 am EST to discuss results for first and second quarters of 2007. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's website at http://www.parpharm.comand will be available for at least 30 days. The dial- in number is 866-770-7120 for domestic callers and 617-213-8065 for international callers. The access number is 88770486. A replay of the conference call will be available commencing approximately one hour after the call. The replay dial-in number is 888-286-8010 for domestic callers and 617- 801-6888 for international callers. The access number is 18960113.

For a copy of Par's Form 10-Qs for the quarterly periods ended March 31, 2007 and June 30, 2007, visit Investors/SEC Filings on the Par web site at http://www.parpharm.com.

Non-GAAP Measures

Par prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). In an effort to provide investors with additional information regarding the Company's results and to provide a meaningful year-over-year comparison of the Company's financial performance, the Company sometimes uses non-GAAP financial measures as defined by the Securities and Exchange Commission. The differences between the U.S. GAAP and non-GAAP financial measures are reconciled in the attached. In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating the Company's underlying business performance. Management uses the non-GAAP financial measures to evaluate the Company's financial performance against internal budgets and targets. In addition, management internally reviews the results of the Company excluding the impact of certain items, as it believes that these non- GAAP financial measures are useful for evaluating the Company's core operating results and facilitating comparison across reporting periods. Importantly, the Company believes non-GAAP financial measures should be considered in addition to, and not in lieu of, U.S. GAAP financial measures. The Company's non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward- looking and, as such, are subject to risks and uncertainties, including the extent and impact of litigation arising out of the accounting issues described in the Company's filings with the Securities and Exchange Commission (SEC), the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the Company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the company's filings with the SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the company assumes no obligation to update any forward-looking statements.

PAR PHARMACEUTICAL COMPANIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share Data)

(Unaudited)

June 30, March 31, December 31,

ASSETS 2007 2007 2006

Current assets:

Cash and cash equivalents $184,238 $141,477 $120,991

Available for sale debt and

marketable equity securities 169,243 119,754 92,120

Accounts receivable, net 47,123 147,030 99,043

Inventories 83,779 87,674 106,322

Prepaid expenses and other current

assets 22,225 23,215 15,833

Deferred income tax assets 72,104 72,104 72,105

Income taxes receivable 6,605 6,608 12,422

Total current assets 585,317 597,862 518,836

Property, plant and equipment, at

cost less accumulated depreciation

and amortization 85,012 86,354 89,155

Available for sale debt and

marketable equity securities 4,680 4,710 7,652

Investment in joint venture 5,387 5,304 5,292

Other investments - 4,588 16,588

Intangible assets, net 41,371 44,674 47,880

Goodwill 63,729 63,729 63,729

Deferred charges and other assets 3,027 6,917 16,000

Non-current deferred income tax

assets, net 49,714 49,278 49,545

Total assets $838,237 $863,416 $814,677

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Short-term and current portion of

long-term debt $200,824 $202,632 $204,469

Accounts payable 32,801 33,690 48,297

Payables due to distribution

agreement partners 73,754 89,635 89,585

Accrued salaries and employee

benefits 13,443 12,444 15,510

Accrued expenses and other current

liabilities 23,112 22,154 18,833

Income taxes payable 4,438 20,815 16,974

Total current liabilities 348,372 381,370 393,668

Long-term debt, less current

portion - - -

Other long-term liabilities 13,482 13,246 -

Commitments and contingencies - - -

Stockholders' equity:

Preferred Stock, par value $0.0001

per share, authorized

6,000,000 shares; none issued and

outstanding - - -

Common Stock, par value $0.01 per

share, authorized 90,000,000

shares, issued 36,345,466 and

36,335,215 and 35,901,276 shares 364 364 359

Additional paid-in-capital 263,446 257,394 254,013

Retained earnings 244,568 241,766 200,256

Accumulated other comprehensive

gain (loss) 2,526 3,209 (431)

T
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
8. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: